Neural Stem Cell Differentiation
Induced Pluripotent Stem Cells (iPSCs) are exceedingly popular because like embryonic stem cells (ESCs), they are pluripotent and can differentiate into all three germ layers with the potential to differentiate into all cell types within the body. And, unlike ESCs they are not encumbered with the ethical dispute associated with the sourcing of ESCs. The true potential of stem cell technology lies in the directed terminal differentiation of iPSCs into specific somatic cells. iPSC-derived cell lines provide an abundant and consistent source of material for studying the science behind human development, drug screening, personalized therapy in regenerative medicine, and disease modeling. The process of iPSC differentiation to neurons and neuronal cells is of special importance for neurobiology and related disorders, considering the dearth of clinically relevant in vitro models available for research, drug screening and development, as well as the lack of therapy to reverse neuronal damage.
At Applied StemCell, we have worked with stem cells, and have improved and expanded on the technology since our establishment. Researchers can leverage our expertise in this field by using our high quality, stem cell differentiation services for deeper understanding of developmental biology, disease mechanisms, therapeutic targets and outcomes. We can differentiate your patient-derived iPSCs into self-renewing, multipotent neural stem cells (NSC) or further into neurons (dopaminergic and motor neurons), and glial cells (oligodendrocytes and astrocytes). We can also generate iPSCs from your patient-derived fibroblasts and PBMCs and then differentiate them.
Benefits and advantages of iPSC differentiation to neurons and glial cells:
- Provides genetic and physiologically relevant in vitro models to study neural development and associated disorders: congenital disorders, neurodegenerative disorders and brain tumors.
- Valuable model for Identifying new targets for neuro-regeneration as opposed to treatments limiting to symptomatic relief or delaying disease progression.
- Allows for future adaptation of technology for regenerative medicine and cell therapy in humans for the treatment of Parkinson’s disease, Lou-Gehrig disease (ALS), Huntington’s disease, and spinal cord injury among other diseases.
- Differentiation of genome engineered in iPSCs (mutation introduction or correction) to neurons, offers an isogenic source of control-disease cell lines for basic research, drug development, hard-to-model neurological disorders, and potentially for gene therapy.
Key features of ASC’s service for iPSC differentiation to neurons and glial cells:
- Rapid Turnaround: Differentiated NSCs in just 7 days; terminal differentiation to neurons or glial cells in 8-12 weeks weeks
- High Purity cells: > 80% neurons expressing typical markers for cell lineage
- Ready-to-use cells for your research and discoveries: simply thaw and culture the cells
- Low passage number ensures robust cells for reliable results
- Fully characterized cells: Cells are characterized for the expression of relevant biomarkers to identify multipotency as in the case of NSC or cell lineage markers. (For example, NSC markers: Pax6 and Sox1; dopaminergic markers: TH; motor neurons: HB9)
iPSC Differentiation into Neural Stem Cells (NSC)
Figure 1. iPSCs can be differentiated to NSC in feeder-free condition with high efficiency using Applied StemCell's proprietary neural induction protocol.
Figure 2. Differentiated NSCs retain neural stem cell phenotype even after free-thaw and passage under feeder-free condtions.
Neural Stem Cells Differentiation Service
|1. Recovery, Expansion and Validation of iPSCs/ESCs||2-3 weeks||
Biweekly updates throughout service
|2. Neural Stem Cells Differentiation (2-6 X10^6 Cells)||2-4 weeks||
|3. Characterization of Differentiated Cells by ICC (per marker)||1 weeks||
- For differentiation of iPSCs into neural stem cells, you will need to provide ~1-2 x 10^6 cells
- 2-6 X10^6 /line, cryopreserved.
- Neural stem cells maintenance medium: 250ml
- Reports: NSC marker staining (ie. SOX1, Pax6) and mycoplasma testing
iPSC Differentiation to Blood Lineage Cells:
Also, ask us about directed differentiation of your iPSCs into hematopoietic stem cells (HSCs) and blood cells. Avoid sourcing problems associated with HSC procurement, and have a consistent and continuous source of mature human blood cells that are otherwise hard to obtain and maintain.
Applications: hematopoiesis, cancer immunotherapy, autoimmune diseases/ transplant graft rejection, and drug screening.